ArticleCytotechnology2020

An investigation of the mechanisms underlying the proteasome inhibitor bortezomib resistance in PC3 prostate cancer cell line.

Azmi Yerlikaya et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.